JPMorgan Chase & Co. bought 1.16 million shares of SINOPHARM (01099) off-exchange at an average of HKD 16.1441 per share on October 30, 2026, involving about HKD 18.65 million; it was an off-exchange cash transaction, not matched on the SEHK open market and therefore not a direct secondary-market dealing.
Prior to the acquisition, JPMorgan Chase & Co.’s long position in SINOPHARM was 66.55 million shares, representing 4.95%; following the acquisition, the holding changed to 67.71 million shares, with the long position ratio rising to 5.04%.